Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients |
| |
| Authors: | Li-Heng Yang Hsin-Shun Tseng Che Lin Li-Sheng Chen Shou-Tung Chen Shou-Jen Kuo Dar-Ren Chen |
| |
| Institution: | 1.Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan.;2.Department of Medical Research, Changhua Christian Hospital, Changhua, Taiwan.;3.Centre of Biostatistics Consultation, National Taiwan University College of Public Health, Taipei, Taiwan.;4.School of Oral Hygiene, Taipei Medical University College of Oral Medicine, Taipei, Taiwan.;5.Comprehensive Breast Cancer Center, Changhua Christian Hospital, Changhua, Taiwan. |
| |
| Abstract: | PurposeThis study aimed to analyze the efficacy and prognostic significance of adjuvant tamoxifen in breast cancer patients with various hormone receptor statuses.MethodsTypically, 1,260 female breast cancer patients were recruited in this study. The correlation between estrogen receptor (ER)/progesterone receptor (PR) phenotypes and clinical characteristics was investigated, and the survival rate was assessed after 5-year follow-up.ResultsThe 5-year overall survival (85%) was better in women under the age of 50 years. Patients with ER+/PR+ tumors had a better 5-year survival rate (94%); those with ER-/PR- tumors experienced the worst outcome (74% survival rate); whereas single-positive cases were in between. In 97 out of 128 patients with ER-/PR+ tumors, tamoxifen was given as adjuvant hormonal therapy, and it increased the survival benefit in the lower grade group in terms of overall survival and disease-free survival (p=0.01 and p=0.03, respectively).ConclusionFor high-grade tumors with ER-/PR+, adjuvant tamoxifen therapy may have no survival benefit, whereas for the patients with low-grade ER-/PR+ tumors, adjuvant tamoxifen therapy is highly suggestive. |
| |
| Keywords: | Breast carcinoma Estrogen receptor Progesterone receptor Tamoxifen |
|
|
